Gilead holds sole rights for clinical development and potential commercialisation of the compounds developed under the deal. Credit: JHVEPhoto/Shutterstock.

Gilead Sciences has announced a strategic partnership with Genesis Therapeutics, aimed at using AI to discover and develop new small molecule therapies.

The deal will utilise the advanced AI technologies of Genesis to generate therapeutic candidates for targets chosen by Gilead.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Genesis’ field-leading AI platform, Genesis Exploration of Molecular Space (GEMS) will be used in the partnership to aid in creating and streamlining molecules for the Gilead-chosen targets.

The collaboration will focus on preclinical research, with Gilead holding sole rights for the clinical development and potential commercialisation of the compounds developed.

Gilead Sciences Research executive vice-president Flavius Martin stated: “The use of generative AI in drug development, enabled by people, science and other new technology, has shown potential to accelerate the discovery of molecules for challenging targets.

“We look forward to working with Genesis to apply their AI platform to discover and advance novel therapies that may address significant unmet patient needs.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Genesis is entitled to receive $35m in upfront payment for three targets, with options for Gilead to nominate additional targets for a fee.

Genesis also stands to gain further financial rewards through preclinical, development, regulatory and commercial milestones, as well as royalty payments on net product sales.

Genesis founder and CEO Evan Feinberg stated: “Many promising protein targets have a paucity of relevant training data, which makes it difficult to apply off-the-shelf machine learning methods.

“We have designed our physical AI platform to address this issue and enable drug discovery campaigns for difficult targets. Genesis is thrilled to combine our expertise in generative AI and drug discovery with Gilead’s deeply experienced research and development teams, with the shared goal of creating breakthrough therapies for patients.”

Genesis had previously secured more than $300m in funding to create a pipeline, targeting high-impact medical conditions.

The latest development comes after Gilead partnered with PANTHERx Rare to distribute LIVDELZI, a treatment for adults with primary biliary cholangitis.